Skip to main content
Top
Published in: BMC Endocrine Disorders 1/2017

Open Access 01-12-2017 | Research article

MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves’ disease and its significance

Authors: Ai Guo, Yan Tan, Chun Liu, Xiaoya Zheng

Published in: BMC Endocrine Disorders | Issue 1/2017

Login to get access

Abstract

Background

MST-4 and TRAF-6 are involved in the regulation of inflammatory and immune responses. However, whether they participate in the pathogenesis of Graves’ disease (GD) has not yet been reported. Therefore, the purpose of this study was to investigate the expression of MST-4 and TRAF-6 in the peripheral blood of patients with GD to understand their role in the pathogenesis of GD.

Methods

Thirty newly diagnosed GD patients, 24 GD patients in remission (eGD) and 30 normal controls (NC) were recruited. Thyroid function and autoantibody levels were determined using a chemiluminescence immunoassay. Peripheral blood mononuclear cells (PBMCs) were extracted, and MST-4 and TRAF-6 mRNA and protein levels were determined using real-time PCR and Western blotting, respectively.

Results

1. Thyroid function in the GD group was significantly different from that in the eGD and NC groups (P < 0.05); however, there was no difference in thyroid function between the eGD group and the NC group (P > 0.05). The autoantibody levels in the NC group were significantly different from those in the GD and eGD groups (P < 0.05); however, the difference in the levels between the GD group and eGD group was not statistically significant (P > 0.05). 2. The MST-4 and TRAF-6 mRNA and protein levels in the GD group were significantly lower than those in the NC group (P < 0.05); however, there were no differences in mRNA and protein levels between the GD group and the eGD group or between the eGD group and the NC group (P > 0.05). 3. The correlation between the MST-4 and TRAF-6 mRNA and protein levels was not significant. However, there was a significant correlation between the TRAF-6 mRNA and TPO Ab levels in the eGD group and between the TRAF-6 mRNA and TR Ab levels in the NC group.

Conclusion

The MST-4 and TRAF-6 mRNA and protein levels were lower in the GD group than in the NC group, suggesting that MST-4 and TRAF-6 may be important in the pathogenesis of GD. Whether MST-4 influences the innate immune response through TRAF-6 and thus regulates the imbalance in downstream effector T cells requires further study. Investigating the expression of MST-4 and TRAF-6 in GD can provide a new perspective and targets for further study of the upstream mechanism responsible for effector T cell imbalance.
Literature
2.
go back to reference Esfahanian F, Naimi E, Doroodgar F, Jadali Z. Th1/Th2 cytokines in patients with Graves’ disease with or without ophthalmopathy. Iran J Allergy Asthma Immunol. 2013;12:168–75.PubMed Esfahanian F, Naimi E, Doroodgar F, Jadali Z. Th1/Th2 cytokines in patients with Graves’ disease with or without ophthalmopathy. Iran J Allergy Asthma Immunol. 2013;12:168–75.PubMed
3.
go back to reference Lv M, Shen J, Li Z, Zhao D, Chen Z, Wan H, et al. [Role of Treg/Th17 cells and related cytokines in Graves’ ophthalmopathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34:1809–13.PubMed Lv M, Shen J, Li Z, Zhao D, Chen Z, Wan H, et al. [Role of Treg/Th17 cells and related cytokines in Graves’ ophthalmopathy]. Nan Fang Yi Ke Da Xue Xue Bao. 2014;34:1809–13.PubMed
9.
go back to reference Mohammad Hosseini A, Majidi J, Baradaran B, Yousefi M. Toll-like receptors in the pathogenesis of autoimmune diseases. Adv Pharm Bull. 2015;5:605–14. 10.15171/apb.2015.082.CrossRefPubMedPubMedCentral Mohammad Hosseini A, Majidi J, Baradaran B, Yousefi M. Toll-like receptors in the pathogenesis of autoimmune diseases. Adv Pharm Bull. 2015;5:605–14. 10.15171/apb.2015.082.CrossRefPubMedPubMedCentral
10.
go back to reference Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351–61. doi:10.1016/S0092-8674(00)00126-4.CrossRefPubMed Deng L, Wang C, Spencer E, Yang L, Braun A, You J, et al. Activation of the IkappaB kinase complex by TRAF6 requires a dimeric ubiquitin-conjugating enzyme complex and a unique polyubiquitin chain. Cell. 2000;103:351–61. doi:10.​1016/​S0092-8674(00)00126-4.CrossRefPubMed
13.
go back to reference Jiao S, Zhang Z, Li C, Huang M, Shi Z, Wang Y, et al. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat Immunol. 2015;16:246–57. doi:10.1038/ni.3097.CrossRefPubMed Jiao S, Zhang Z, Li C, Huang M, Shi Z, Wang Y, et al. The kinase MST4 limits inflammatory responses through direct phosphorylation of the adaptor TRAF6. Nat Immunol. 2015;16:246–57. doi:10.​1038/​ni.​3097.CrossRefPubMed
14.
go back to reference Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646. doi:10.1089/thy.2010.0417.CrossRefPubMed Bahn Chair RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of the American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646. doi:10.​1089/​thy.​2010.​0417.CrossRefPubMed
16.
go back to reference Sung V, Luo W, Qian D, Lee I, Jallal B, Gishizky M. The Ste20 kinase MST4 plays a role in prostate cancer progression. Cancer Res. 2003;63:3356–63.PubMed Sung V, Luo W, Qian D, Lee I, Jallal B, Gishizky M. The Ste20 kinase MST4 plays a role in prostate cancer progression. Cancer Res. 2003;63:3356–63.PubMed
17.
go back to reference Lin ZH, Wang L, Zhang JB, Liu Y, Li XQ, Guo L, et al. MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway. Int J Oncol. 2014;45:629–40. doi:10.3892/ijo.2014.2455.PubMed Lin ZH, Wang L, Zhang JB, Liu Y, Li XQ, Guo L, et al. MST4 promotes hepatocellular carcinoma epithelial-mesenchymal transition and metastasis via activation of the p-ERK pathway. Int J Oncol. 2014;45:629–40. doi:10.​3892/​ijo.​2014.​2455.PubMed
19.
26.
go back to reference Li XF, Li Q, Chen ZJ, Liu C. Change of serum heat shock protein 70 in Graves disease and its significance. Chinese General Practice. 2012;18:2028–30 (In Chinese). Li XF, Li Q, Chen ZJ, Liu C. Change of serum heat shock protein 70 in Graves disease and its significance. Chinese General Practice. 2012;18:2028–30 (In Chinese).
27.
go back to reference Peng SQ, Li CY, Yu XH, Liu X, Jing T. The expression of toll-like receptors in peripheral blood mononuclear cells of patients with autoimmune thyroid disease and their clinical significances. In: The 13th Annual Meeting of Chinese Society of Endocrinology. 2014. In Chinese. Peng SQ, Li CY, Yu XH, Liu X, Jing T. The expression of toll-like receptors in peripheral blood mononuclear cells of patients with autoimmune thyroid disease and their clinical significances. In: The 13th Annual Meeting of Chinese Society of Endocrinology. 2014. In Chinese.
29.
go back to reference He K, Hu Y, Mao X. Abnormal proportions of immune regulatory cells and their subsets in peripheral blood of patients with Graves’ disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30:1190–3.PubMed He K, Hu Y, Mao X. Abnormal proportions of immune regulatory cells and their subsets in peripheral blood of patients with Graves’ disease. Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2014;30:1190–3.PubMed
30.
go back to reference Hassan I, Brendel C, Zielke A, Burchert A, Danila R. Immune regulatory plasmacytoid dendritic cells selectively accumulate in perithyroidal lymph nodes of patients with Graves disease: implications for the understanding of autoimmunity. Rev Med Chir Soc Med Nat Iasi. 2013;117:46–51.PubMed Hassan I, Brendel C, Zielke A, Burchert A, Danila R. Immune regulatory plasmacytoid dendritic cells selectively accumulate in perithyroidal lymph nodes of patients with Graves disease: implications for the understanding of autoimmunity. Rev Med Chir Soc Med Nat Iasi. 2013;117:46–51.PubMed
31.
go back to reference He XL, Li XP, Tao JH, Chen ZQ, Li XM. The expression of miR-146a TRAF6 IRAK-1 in the peripheral blood mononuclear cells of patients with ankylosing spondylitis. In: The 17th conference of the Chinese Rheumatology Association. 2012. In Chinese. He XL, Li XP, Tao JH, Chen ZQ, Li XM. The expression of miR-146a TRAF6 IRAK-1 in the peripheral blood mononuclear cells of patients with ankylosing spondylitis. In: The 17th conference of the Chinese Rheumatology Association. 2012. In Chinese.
32.
go back to reference Zhu LJ, Dai L, Mo YQ, Zheng DH, Zhang BY. The expression of TRAF6 patients with rheumatoid arthritis synovial and significance. In: The 8th Rheumatism Academic Conference Integrated of Traditional and Western Medicine. 2010. In Chinese. Zhu LJ, Dai L, Mo YQ, Zheng DH, Zhang BY. The expression of TRAF6 patients with rheumatoid arthritis synovial and significance. In: The 8th Rheumatism Academic Conference Integrated of Traditional and Western Medicine. 2010. In Chinese.
34.
go back to reference Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7. doi:10.1152/ajpendo.00302.2006.CrossRefPubMed Creely SJ, McTernan PG, Kusminski CM, Fisher FM, Da Silva NF, Khanolkar M, et al. Lipopolysaccharide activates an innate immune system response in human adipose tissue in obesity and type 2 diabetes. Am J Physiol Endocrinol Metab. 2007;292:E740–7. doi:10.​1152/​ajpendo.​00302.​2006.CrossRefPubMed
36.
go back to reference Frobøse H, Rønn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, et al. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol. 2006;20:1587–96. doi:10.1210/me.2005-0301.CrossRefPubMed Frobøse H, Rønn SG, Heding PE, Mendoza H, Cohen P, Mandrup-Poulsen T, et al. Suppressor of cytokine signaling-3 inhibits interleukin-1 signaling by targeting the TRAF-6/TAK1 complex. Mol Endocrinol. 2006;20:1587–96. doi:10.​1210/​me.​2005-0301.CrossRefPubMed
38.
go back to reference King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med. 2006;12:1088–92. doi:10.1038/nm1449.CrossRefPubMed King CG, Kobayashi T, Cejas PJ, Kim T, Yoon K, Kim GK, et al. TRAF6 is a T cell-intrinsic negative regulator required for the maintenance of immune homeostasis. Nat Med. 2006;12:1088–92. doi:10.​1038/​nm1449.CrossRefPubMed
Metadata
Title
MST-4 and TRAF-6 expression in the peripheral blood mononuclear cells of patients with Graves’ disease and its significance
Authors
Ai Guo
Yan Tan
Chun Liu
Xiaoya Zheng
Publication date
01-12-2017
Publisher
BioMed Central
Published in
BMC Endocrine Disorders / Issue 1/2017
Electronic ISSN: 1472-6823
DOI
https://doi.org/10.1186/s12902-017-0161-y

Other articles of this Issue 1/2017

BMC Endocrine Disorders 1/2017 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.